Case 360°™: Appropriate Management of Patients With Hemophilia B

Click the “Start Program” button to indicate you have reviewed the CME/CE information for this activity.
Start Program


Release Date: November 14, 2017
Expiration Date: November 14, 2018
Estimated Time to Complete Activity: 60 minutes
Minimum System Requirements:
  • Internet Explorer 10 (or higher)
  • Mozilla Firefox 48 (or higher)
  • Google Chrome (latest version)
  • Adobe Acrobat 15.0 (or higher)
  • Screen resolution 1024 x 768
Click here to contact Postgraduate Institute for Medicine (PIM)

Target Audience
This activity has been designed to meet the educational needs of hematologists, hematologist/oncologists, pediatricians, physician assistants, registered nurses, advanced practice registered nurses, pharmacists, and other specialists in the hemophilia treatment center (HTC) team, as well as other healthcare providers (HCPs) interested in new developments in the management of complications in patients with hemophilia.  

Statement of Need/Program Overview
Hemophilia B (HB) is a potentially devastating and currently incurable disease. Optimal management of patients requires knowledge of the effect of HB on patients as well as a foundational understanding of the disease, its impact, available treatments, and new developments in the field. Additionally, new research has uncovered the differentiation of bleeding phenotypes and their relation to long-term outcomes. This educational program has been developed to meet these needs and educate HCPs involved in treating and managing patients with HB to allow for informed and improved outcomes in the real-world setting.

Educational Objectives
After participating in this activity, participants should be able to:

  • Review the impact of hemophilia B on patients, including quality-of-life issues
  • Discuss current challenges and new developments in the management of patients with hemophilia B
  • Assess current data and review expert opinion about novel treatments and management strategies

Presenting Faculty

Chair
Robert Sidonio
Robert Sidonio Jr, MD
Associate Director of Hemostasis and Thrombosis, Comprehensive Bleeding Disorder Center,
Emory University and Children’s Healthcare of Atlanta, Atlanta, GA

Faculty
Chris Guelcher
Chris Guelcher, Hemostasis RN-BC, MS, PPCNP-BC
Lead Advanced Practice Provider, Center for Cancer and Blood Disorders
Children's National Health System, Washington, DC

Michelle L Witkop
Michelle L. Witkop, DNP, FNP-BC
Head of Research, National Hemophilia Foundation, New York, NY
Bleeding Disorders Nurse Practitioner, Northern Regional Bleeding Disorders Center
Munson Medical Center, Traverse City, MI 

Physician Continuing Medical Education
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine, the Cardiovascular & Metabolic Health Foundation, and Educational Concepts in Medicine. Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians

Credit Designation
Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education
Credit Designation
This educational activity for 1.0 contact hours is provided by Postgraduate Institute for Medicine. Designated for 0.5 contact hours of pharmacotherapy credit for Advance Practice Registered Nurses.

Accreditation Statement
Postgraduate Institute for Medicine is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

 

Method of Participation
During the period of November 14, 2017, through November 14, 2018, participants must:

  • Read the learning objectives and faculty disclosures
  • Study the educational activity
  • Complete the posttest by recording the best answer to each question
  • Complete the evaluation form

A statement of credit will be issued automatically upon successful completion of the post-activity survey with a score of 75% or better and submitting the activity evaluation.

Fee Information & Refund/Cancellation Policy
There is no fee for this educational activity.

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by PIM for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. 

PIM is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest. 

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity: 

Name of Faculty Presenter/Planning Committee Reported Financial Relationship
Robert Sidonio Jr, MD

Consulting Fees: Aptevo Therapeutics; Bayer; Bioverativ; CSL Behring; Grifols; Novo Nordisk, Inc.; Octapharma; Pfizer Inc.; Shire
Contracted Research: Bioverativ; Grifols; Shire

Chris Guelcher, Hemostasis RN-BC, MS, PPCNP-BC

Consulting Fees: Bioverativ; Genentech, Inc.; HEMA Biologics; Novo Nordisk, Inc.; Octapharma; Pfizer Inc.
Other/Non-profit boards/Patents: ATHN Board Secretary; NHF Steering Committees; THSNA Nurse Liaison; WFH US Nurse Representative

Michelle L. Witkop, DNP, FNP-BC Consulting Fees: Aptevo Therapeutics; Baxalta; CSL Behring; Medscape; Novo Nordisk, Inc.; Pfizer Inc.
Contracted Research: Bioverativ
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Name of Planner or Manager Reported Financial Relationship
PIM Clinical Reviewers: Trace Hutchison, PharmD; Samantha Mattiucci, PharmD, CHCP; Judi Smelker-Mitchek, RN, BSN; Jan Schultz, RN, MSN, CHCP 

Have no real or apparent conflicts of interest to report.

Educational Concepts in Medicine: Patrick J. Crowley, MBA, Partner/CEO; Jodi Andrews, BS, Partner/COO; Debbie Anderson, PhD, MT(ASCP)SH, Medical Writer; Helen Morfit, BA, Program Director Have no real or apparent conflicts of interest to report.

MEDIA
Internet

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. 

Support
This activity is supported by an educational grant from Novo Nordisk.

This activity is jointly provided by: